Company: MYSEW
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001013762-25-004290
Chunk: 545

Company: Myseum, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 2
Chunk 545
---
 shall be automatically retired and restored to the status of an authorized but unissued share of Preferred Stock, effective
immediately after such Redemption.

On August 4, 2023, the Company issued 2,000,000
of Series B preferred for aggregate cash of $1,000.

Common Stock

Sale of Common Stock and Warrants

On January 16, 2024, the Company entered into
an underwriting agreement (the “Underwriting Agreement”) with EF Hutton LLC (the “Representative”), as the representative
of the underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”)
of 382,972 shares of the Company’s common stock (the “Shares”) and pre-funded warrants to purchase up to 590,000 shares
of Common Stock (the “Pre-Funded Warrants”). The public offering price for each share of Common Stock was $1.85 for aggregate
gross proceeds of $708,498, and public offering price for the Pre-Funded Warrants was $1.8499 for each Pre-Funded Warrant for aggregate
gross proceeds of $1,091,441. In connection with this Offering, the Company raised aggregate gross proceeds of $1,799,939 and received
net proceeds of $1,420,773, net of Underwriters discounts and offering costs of $279,166 and legal fees of $100,000.

The per share exercise price for the Pre-Funded
Warrants was $0.0001 and the Pre-Funded Warrants were exercisable immediately. The Underwriters immediately exercised the 590,000 Pre-Funded
Warrants and the Underwriters received 589,981 shares of Common Stock since the exercise was cashless. The Pre-Funded Warrants are not
and will not be listed for trading on any national securities exchange or other nationally recognized trading system.

F-19

DATCHAT, INC. AND SUBSIDIARIES AND CONSOLIDATED ENTITIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2024 and 2023

The Company is using the net proceeds from the
Offering for general corporate purposes, for sales and marketing and for research and development.

The Underwriting Agreement contained customary
representations, warranties and covenants made by the Company. It also provided for customary indemnification by each of the Company and
the Underwriters, severally and not jointly,